EWTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Edgewise Therapeutics Inc (EWTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline, the lack of immediate catalysts, neutral technical indicators, and ongoing uncertainties in its clinical trials suggest that holding off on investment is prudent until more clarity emerges or stronger positive signals are observed.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 45.872, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading below the pivot level of 30.009, with support at 28.621 and resistance at 31.397. Overall, the technical indicators suggest a neutral to slightly bearish trend.
The company has $530.1 million in cash reserves, providing a strong financial cushion. Positive mid-stage trial data for its heart disease therapy was presented at the J.P. Morgan Healthcare Conference, reinforcing its potential in the HCM treatment space.
Uncertainty remains around the safety profile of EDG-7500, with concerns about atrial fibrillation. Key data points for EDG-7500 and other pipeline developments are years away, delaying significant catalysts. The stock is also trending slightly bearish in the short term.
In Q3 2025, the company reported no revenue growth and a net loss of $40.67 million, though net income improved by 19.15% YoY. EPS increased to -0.39, up 8.33% YoY, reflecting slight operational improvements but no profitability.
Analysts are mixed but lean positive. JPMorgan and Truist maintain bullish views, citing the potential of EDG-7500, while Stifel highlights safety concerns and the long timeline for meaningful data. Price targets range from $42 to $46, indicating potential upside but contingent on future trial results.
